A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy

Trial Profile

A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ROYAL-1
  • Sponsors Gemphire Therapeutics
  • Most Recent Events

    • 13 Nov 2017 Results published in the Gemphire Therapeutics Media Release.
    • 13 Nov 2017 According to a Gemphire Therapeutics media release, company presented the data at the American Heart Associations (AHA) Scientific Sessions in Anaheim, California on November 2017 showing that gemcabene significantly reduces atherogenic remnant lipoprotein and LDL-C as add-on to statins in a cardiometabolic population.
    • 11 Nov 2017 Trial design and other study details presented at the 90th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top